Brookings conference on post-market safety
Brookings Institution's Engelberg Center for Health Care Reform will hold a conference in Washington, D.C., June 13 on drug safety and post-market evidence, hosted by center Director Mark McClellan. During the conference, FDA Commissioner Andrew von Eschenbach and CDER Director Janet Woodcock are scheduled to discuss the agency's new Sentinel initiative, along with Richard Platt, Harvard University, Marcus Wilson, from WellPoint's HealthCore unit, and Janet Marchibroda, eHealth Initiative. Some details on the Sentinel project were announced by FDA May 22. Other conference participants will include Garry Neil, J&J, and Arnold Chan, i3 Drug Safety
You may also be interested in...
The Reagan-Udall Foundation is an early priority for FDA in implementing the landmark legislation enacted by Congress in 2007. It is also a lightning road for criticism from Congress about the agency's relationship with regulated industry. We asked foundation chairman Mark McClellan for a status report.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.
Health technology assessment body NICE has now recommended that selective internal radiation therapy can be used on England’s National Health Service for treating advanced liver cancer.